Literature DB >> 4028870

Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration.

K Borner, H Lode, B Hampel, M Pfeuffer, P Koeppe.   

Abstract

The pharmacokinetics of ceftriaxone (CRO) after subcutaneous and intravenous administration was studied in 10 healthy volunteers (5 males, 5 females, age 22-43 years, body weight 64.3 +/- 9.5 kg). Each of them received 2.0 g CRO i.v., and then 0.5 g i.v. and 0.5 g CRO s.c. in a randomized cross-over design. Subcutaneous administration of ceftriaxone was tolerable in combination with lidocaine. Serum and urine concentrations were determined by high performance liquid chromatography and for comparison with a bioassay. Mean serum concentrations were high after intravenous administration: 258 +/- 40 mg/1 (0 min, 2 g i.v.) resp. 84 +/- 40 mg/1 (0 min, 0.5 g i.v.). They declined to 11.6 +/- 4.2 mg/1 (2 g) resp. 6.5 +/- 2.2 mg/1 (0.5 g i.v.) within 24 h. Following subcutaneous application peak serum concentrations of 37.1 +/- 5.6 mg/1 were found after 138 +/- 49 min and a mean serum concentration of 6.6 +/- 1.6 mg/1 after 24 h. Concentrations of free ceftriaxone, determined by ultrafiltration, were 9.2 +/- 2.7% of total concentrations from 25 to 200 mg/1. Cumulated urine recoveries over a period of 24 h were: 51.2 +/- 8.9% (2 g i.v.), 47.1 +/- 7.9% (0.5 g i.v.) and 39.7 +/- 9.5% (0.5 g s.c.). There was no evidence for the presence of a microbiologically active metabolite in urine. Comparison of pharmacokinetic parameters for the 0.5 g dose did not show relevant differences between intravenous and subcutaneous administration (using an open two-compartment model): t beta 1/2 (min) 514 +/- 104 (s.c.), 592 +/- 133 (i.v.), VD,Area (1) 11.9 +/- 3.8 (s.c.), 13.3 +/- 3.8 (i.v.) and AUCtot (mg X h/1) 515 +/- 106 (s.c.) and 549 +/- 125 (i.v.). Bioavailability of the subcutaneous application was 0.96 +/- 0.26. For the 2 g i.v. dose the known nondosis-dependent kinetics was observed. Subcutaneous administration of ceftriaxone appears to be a possible alternative to the intravenous route in selected clinical situations or cases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4028870     DOI: 10.1159/000238342

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  8 in total

Review 1.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

3.  Influence of assay methodology on the measurement of free serum ceftriaxone concentrations.

Authors:  S J Kohlhepp; D N Gilbert; J E Leggett
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 4.  Ceftriaxone as a Novel Therapeutic Agent for Hyperglutamatergic States: Bridging the Gap Between Preclinical Results and Clinical Translation.

Authors:  Osama A Abulseoud; Fawaz Alasmari; Abdelaziz M Hussein; Youssef Sari
Journal:  Front Neurosci       Date:  2022-07-05       Impact factor: 5.152

5.  Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.

Authors:  A del Río; C García-de-la-Mària; J M Entenza; O Gasch; Y Armero; D Soy; C A Mestres; J M Pericás; C Falces; S Ninot; M Almela; C Cervera; J M Gatell; A Moreno; P Moreillon; F Marco; J M Miró
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

Review 7.  Managing infective endocarditis in the elderly: new issues for an old disease.

Authors:  Emmanuel Forestier; Thibaut Fraisse; Claire Roubaud-Baudron; Christine Selton-Suty; Leonardo Pagani
Journal:  Clin Interv Aging       Date:  2016-09-02       Impact factor: 4.458

8.  Prevention of Surgical Site Infections and Biofilms: Pharmacokinetics of Subcutaneous Cefazolin and Metronidazole in a Tumescent Lidocaine Solution.

Authors:  Jeffrey A Klein; Loralie J Langman
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-05-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.